Thymic Peptides: Thymosin Alpha-1, Thymosin Beta-4 and the Thymus-Derived Peptide Family

Introduction

The phrase "thymic peptides" covers a set of molecules that share a point of origin rather than a common structure. Each was first isolated from thymus tissue, purified from blood on the strength of a thymus-dependent activity, or synthesized as a fragment or derivative of one of those molecules. The best known members, thymosin alpha-1 and thymosin beta-4, came from the same calf-thymus preparation and carry the same family name, yet they are encoded by different genes, differ in length and sequence, and have accumulated entirely separate research records. This overview sets out the classification and discovery history of the family, explains how the synthetic fragment TB-500 relates to thymosin beta-4, and reports the regulatory status of each compound as a matter of public record. A general research overview of what peptides are provides background on peptide chemistry.

What "thymic peptide" means

The term arose from mid-twentieth-century work establishing that the thymus produced soluble factors that could be extracted and assayed. Three independent research programs contributed the molecules now grouped under the name:

• The thymosin fraction 5 lineage of Abraham White and Allan L. Goldstein, which produced thymosin alpha-1 and thymosin beta-4, among others [1, 2, 3].
• The thymopoietin lineage of Gideon Goldstein (no relation), which produced thymopoietin and its synthetic pentapeptide fragment thymopentin [8, 9, 10].
• The serum thymic factor lineage of Jean-François Bach and Mireille Dardenne, which produced thymulin [11, 12].

A fourth, later group consists of short synthetic peptides derived from thymic extracts in the Russian bioregulator program associated with Vladimir Khavinson, of which the dipeptide Glu-Trp is the most cited example [13].

Because the grouping is historical, it carries no implication that the members act alike.

The thymosin fraction 5 lineage

In 1966, Goldstein, Slater and White published the preparation, assay and partial purification of a thymic lymphocytopoietic factor from calf thymus, naming the preparation "thymosin" [1]. A 1972 paper by Goldstein, Guha, Zatz, Hardy and White described further purification of the preparation [2]. By the early 1970s the group's working material was designated thymosin fraction 5, a heat-stable, partially purified extract containing multiple acidic peptides. Goldstein's 2007 narrative history recounts how the components of fraction 5 were named by Greek letter according to electrophoretic mobility (alpha most acidic, beta intermediate, gamma most basic), with a subscript number assigned in order of isolation [3].

Thymosin alpha-1

Thymosin alpha-1 was the first component of fraction 5 to be sequenced. Goldstein, Low, McAdoo and colleagues reported the complete 28-residue sequence in the Proceedings of the National Academy of Sciences in 1977, describing a heat-stable, highly acidic peptide bearing an N-terminal acetyl group [4]. Low and colleagues published the accompanying isolation and characterization data in the Journal of Biological Chemistry in 1979 [5]. In 1984, Haritos, Goodall and Horecker identified prothymosin alpha, a larger precursor protein, as the source from which thymosin alpha-1 is cleaved [6]. Its synthetic form, thymalfasin, is chemically identical to the natural peptide. The published research record is surveyed in the thymosin alpha-1 research overview; research-grade thymosin alpha-1 reference material is cataloged with per-batch certificates of analysis.

Thymosin beta-4

Thymosin beta-4 was sequenced four years later. Low, Hu and Goldstein reported the complete 43-residue sequence of bovine thymosin beta-4 in 1981 [7]. Hannappel and colleagues then reported in 1982 that the peptide was present in a wide range of rat and mouse tissues, not only the thymus [14]. The decisive reclassification came in 1991, when Safer, Elzinga and Nachmias showed that thymosin beta-4 and Fx, an actin-sequestering peptide isolated from platelets, were indistinguishable [15]. From that point the beta-thymosins were understood principally as G-actin binding proteins of the cytoskeleton, a view consolidated in a 2001 review by Huff, Müller, Otto, Netzker and Hannappel [16].

Alpha and beta thymosins: why the names mislead

The Greek-letter names describe electrophoretic position in a 1970s fractionation scheme, not a family of related sequences. Thymosin alpha-1 is a 28-residue fragment of prothymosin alpha; thymosin beta-4 is a 43-residue product of a separate gene, and the two are studied by different research communities with different questions. The alpha-1 literature concerns interactions with Toll-like receptor pathways on dendritic cells, as reported by Romani and colleagues in 2006 [17]; the beta-4 literature concerns actin dynamics and cell motility [15, 16]. A structural and regulatory comparison of the two is set out in the thymosin alpha-1 vs TB-500 article. A finding reported for one thymosin does not transfer to the other.

TB-500 and thymosin beta-4

Between 1991 and 2003, several groups mapped which part of thymosin beta-4 accounts for its actin binding. Hannappel and Wartenberg reported in 1993 that fragments of thymosin beta-4 retained measurable actin-sequestering ability in a DNase I inhibition assay, with the central region carrying most of the activity [18]. Philp, Huff, Gho, Hannappel and Kleinman reported in 2003 that the actin-binding site of thymosin beta-4, the heptapeptide LKKTETQ at residues 17 to 23, reproduced certain effects of the full-length peptide in their endothelial-cell and mouse models [19].

TB-500 is a synthetic product built on that fragment. In 2012, Esposito, Deventer, Goeman, Van der Eycken and Van Eenoo, writing in Drug Testing and Analysis, synthesized and characterized the N-terminal acetylated 17-23 fragment of thymosin beta-4 that they identified in TB-500, a product they described as suspected to possess doping potential; the active content was Ac-Leu-Lys-Lys-Thr-Glu-Thr-Gln, with a molecular weight of approximately 839 daltons [20]. In the same year, Ho and colleagues published a mass-spectrometry method for detecting TB-500 in equine urine and plasma [21]. TB-500 is therefore not thymosin beta-4; it is a seven-residue synthetic fragment corresponding to the parent molecule's actin-binding motif. The published record on the fragment and its parent is summarized in the TB-500 research overview; research-grade TB-500 is supplied as a laboratory reference material.

Thymopoietin and thymopentin

Working independently of the thymosin program, Gideon Goldstein reported the isolation of "thymin," a polypeptide from bovine thymus, in Nature in 1974 [8]; the molecule was renamed thymopoietin to avoid confusion with the pyrimidine base of the same name. Schlesinger and Goldstein published the amino acid sequence of thymopoietin II, a 49-residue polypeptide, in Cell in 1975 [9]. In 1979, Goldstein, Scheid, Boyse, Schlesinger and Van Wauwe reported in Science that a synthetic pentapeptide corresponding to residues 32 to 36, Arg-Lys-Asp-Val-Tyr, reproduced the biological activity of the parent polypeptide in their in vitro assays [10]. That pentapeptide, thymopentin (TP-5), was studied clinically in the 1980s. Thymopoietin has no sequence relationship to the thymosins.

Thymulin (serum thymic factor)

Thymulin followed a different route: Bach and Dardenne purified a factor from pig serum whose activity disappeared after thymectomy. Dardenne, Pleau, Man and Bach reported the isolation and purification of this circulating thymic factor in the Journal of Biological Chemistry in 1977 [11], and Pleau, Dardenne, Blouquit and Bach reported its amino acid sequence in the companion paper: a nonapeptide, pGlu-Ala-Lys-Ser-Gln-Gly-Gly-Ser-Asn [12]. The molecule was originally called facteur thymique sérique (FTS) and later renamed thymulin. It has no sequence relationship to either thymosin or thymopoietin.

Thymogen (Glu-Trp)

The dipeptide L-glutamyl-L-tryptophan (Glu-Trp) belongs to the Russian peptide bioregulator program. Anisimov, Khavinson and Morozov reported in Biogerontology in 2000 that the dipeptide had been isolated by reverse-phase HPLC from Thymalin, a calf-thymus peptide complex, and that a synthetic pharmaceutical based on it later received the brand name Thymogen [13]. Most of the literature on Thymogen is published in Russian-language journals, and the compound has no FDA or EMA approval.

Regulatory framing

Regulatory status varies across the family:

• Thymalfasin (thymosin alpha-1, Zadaxin) is approved in a number of countries outside the United States, with hepatitis B as its primary labeled indication according to the 2002 industry review by Billich and the 2020 review by Dominari and colleagues [22, 23]. It is not FDA-approved. It holds FDA orphan-drug designations, which confer development incentives without constituting marketing authorization, and it was reviewed by the FDA's Pharmacy Compounding Advisory Committee in 2024 [24].
• Thymosin beta-4 is an investigational compound. RegeneRx Biopharmaceuticals has sponsored clinical trials of the full-length peptide, including a phase 2 randomized trial in dry eye reported by Sosne, Dunn and Kim in 2015 [25] and a phase 3 trial of the RGN-259 ophthalmic formulation reported by Bonini and colleagues in 2022 [26]. It is not approved in any jurisdiction.
• TB-500 has never been approved by the FDA, the EMA or any equivalent regulator, and no clinical trial of the heptapeptide fragment appears in the published record. Thymosin beta-4 and its derivatives, including TB-500, are listed under section S2 of the World Anti-Doping Agency Prohibited List [27]. It is available only as a research-use-only material.
• Thymopentin was studied clinically in the 1980s but is not an FDA-approved drug.
• Thymulin and Thymogen hold no FDA or EMA approval.

Research-grade thymic peptides sold by chemical suppliers are laboratory reference materials, strictly for research use only. The existence of approved thymalfasin products in other jurisdictions does not extend any approval to research-grade material.

Summary table

Compound	Lineage	Structure	Origin	Regulatory status
Thymosin alpha-1 (thymalfasin)	Thymosin fraction 5 (A. L. Goldstein)	28 residues, N-acetylated, acidic; cleaved from prothymosin alpha	Calf thymus, sequenced 1977 [4]	Approved outside the US as Zadaxin; not FDA-approved; FDA orphan designations [22, 23, 24]
Thymosin beta-4	Thymosin fraction 5 (A. L. Goldstein)	43 residues; G-actin sequestering	Calf thymus, sequenced 1981 [7]; later found in most tissues [14]	Investigational (RegeneRx); not approved [25, 26]
TB-500	Synthetic fragment of thymosin beta-4	Ac-LKKTETQ heptapeptide, ~839 Da	Synthetic, characterized 2012 [20]	Not approved; research use only; WADA S2 [27]
Thymopoietin	G. Goldstein	49-residue polypeptide	Bovine thymus, sequenced 1975 [9]	Not approved
Thymopentin (TP-5)	Synthetic fragment of thymopoietin	Arg-Lys-Asp-Val-Tyr pentapeptide	Synthetic, reported 1979 [10]	Studied clinically in the 1980s; not FDA-approved
Thymulin (FTS)	Bach and Dardenne	Nonapeptide, pGlu-Ala-Lys-Ser-Gln-Gly-Gly-Ser-Asn	Pig serum, sequenced 1977 [11, 12]	Not approved
Thymogen	Khavinson bioregulator program	Glu-Trp dipeptide	Isolated from Thymalin extract, synthetic product [13]	Russian marketing; no FDA or EMA approval

Summary

Thymic peptides are a family by history, not by chemistry. The thymosin fraction 5 program produced thymosin alpha-1, a 28-residue fragment of prothymosin alpha, and thymosin beta-4, a 43-residue actin-sequestering peptide, whose shared name reflects an electrophoretic naming scheme rather than structural kinship. TB-500 is a synthetic seven-residue fragment of thymosin beta-4, characterized by Esposito and colleagues in 2012, not the parent molecule. Thymopoietin and thymopentin, thymulin and Glu-Trp complete the classification, each with an independent lineage. Only thymalfasin holds marketing approval anywhere, and none of the family is FDA-approved.

References

1. Goldstein AL, Slater FD, White A. Preparation, assay, and partial purification of a thymic lymphocytopoietic factor (thymosin). Proc Natl Acad Sci USA. 1966;56(3):1010-1017. PMID: 5230175. PubMed
2. Goldstein AL, Guha A, Zatz MM, Hardy MA, White A. Purification and biological activity of thymosin, a hormone of the thymus gland. Proc Natl Acad Sci USA. 1972;69(7):1800-1803. PMID: 4505657. PubMed
3. Goldstein AL. History of the discovery of the thymosins. Ann N Y Acad Sci. 2007;1112:1-13. PMID: 17600284. DOI: 10.1196/annals.1415.001
4. Goldstein AL, Low TL, McAdoo M, McClure J, Thurman GB, Rossio J, et al. Thymosin alpha1: isolation and sequence analysis of an immunologically active thymic polypeptide. Proc Natl Acad Sci USA. 1977;74(2):725-729. PMID: 265536. PMC392366
5. Low TL, Thurman GB, McAdoo M, McClure J, Rossio JL, Naylor PH, Goldstein AL. The chemistry and biology of thymosin. I. Isolation, characterization, and biological activities of thymosin alpha1 and polypeptide beta1 from calf thymus. J Biol Chem. 1979;254(3):981-986. PMID: 216684. PubMed
6. Haritos AA, Goodall GJ, Horecker BL. Prothymosin alpha: isolation and properties of the major immunoreactive form of thymosin alpha 1 in rat thymus. Proc Natl Acad Sci USA. 1984;81(4):1008-1011. PMID: 6583693. DOI: 10.1073/pnas.81.4.1008
7. Low TL, Hu SK, Goldstein AL. Complete amino acid sequence of bovine thymosin beta 4: a thymic hormone that induces terminal deoxynucleotidyl transferase activity in thymocyte populations. Proc Natl Acad Sci USA. 1981;78(2):1162-1166. PMID: 6940133. PubMed
8. Goldstein G. Isolation of bovine thymin: a polypeptide hormone of the thymus. Nature. 1974;247(5435):11-14. PMID: 4128781. PubMed
9. Schlesinger DH, Goldstein G. The amino acid sequence of thymopoietin II. Cell. 1975;5(4):361-365. PMID: 1171728. PubMed
10. Goldstein G, Scheid MP, Boyse EA, Schlesinger DH, Van Wauwe J. A synthetic pentapeptide with biological activity characteristic of the thymic hormone thymopoietin. Science. 1979;204(4399):1309-1310. PMID: 451537. PubMed
11. Dardenne M, Pleau JM, Man NK, Bach JF. Structural study of circulating thymic factor: a peptide isolated from pig serum. I. Isolation and purification. J Biol Chem. 1977;252(22):8040-8044. PMID: 303241. PubMed
12. Pleau JM, Dardenne M, Blouquit Y, Bach JF. Structural study of circulating thymic factor: a peptide isolated from pig serum. II. Amino acid sequence. J Biol Chem. 1977;252(22):8045-8047. PMID: 914862. PubMed
13. Anisimov VN, Khavinson VK, Morozov VG. Immunomodulatory synthetic dipeptide L-Glu-L-Trp slows down aging and inhibits spontaneous carcinogenesis in rats. Biogerontology. 2000;1(1):55-59. PMID: 11707921. DOI: 10.1023/a:1010042008969
14. Hannappel E, Xu GJ, Morgan J, Hempstead J, Horecker BL. Thymosin beta 4: a ubiquitous peptide in rat and mouse tissues. Proc Natl Acad Sci USA. 1982;79(7):2172-2175. PMID: 6954532. DOI: 10.1073/pnas.79.7.2172
15. Safer D, Elzinga M, Nachmias VT. Thymosin beta 4 and Fx, an actin-sequestering peptide, are indistinguishable. J Biol Chem. 1991;266(7):4029-4032. PMID: 1999398. PubMed
16. Huff T, Müller CS, Otto AM, Netzker R, Hannappel E. beta-Thymosins, small acidic peptides with multiple functions. Int J Biochem Cell Biol. 2001;33(3):205-220. PMID: 11311852. PubMed
17. Romani L, Bistoni F, Gaziano R, Bozza S, Montagnoli C, Perruccio K, et al. Thymosin alpha 1 activates dendritic cell tryptophan catabolism and establishes a regulatory environment for balance of inflammation and tolerance. Blood. 2006;108(7):2265-2274. PMID: 16741252. DOI: 10.1182/blood-2006-02-004762
18. Hannappel E, Wartenberg F. Actin-sequestering ability of thymosin beta 4, thymosin beta 4 fragments, and thymosin beta 4-like peptides as assessed by the DNase I inhibition assay. Biol Chem Hoppe Seyler. 1993;374(2):117-122. PMID: 8471179. DOI: 10.1515/bchm3.1993.374.1-6.117
19. Philp D, Huff T, Gho YS, Hannappel E, Kleinman HK. The actin binding site on thymosin beta4 promotes angiogenesis. FASEB J. 2003;17(14):2103-2105. PMID: 14500546. DOI: 10.1096/fj.03-0121fje
20. Esposito S, Deventer K, Goeman J, Van der Eycken J, Van Eenoo P. Synthesis and characterization of the N-terminal acetylated 17-23 fragment of thymosin beta 4 identified in TB-500, a product suspected to possess doping potential. Drug Test Anal. 2012;4(9):733-738. PMID: 22962027. DOI: 10.1002/dta.1402
21. Ho EN, Kwok WH, Lau MY, Wong AS, Wan TS, Lam KK, et al. Doping control analysis of TB-500, a synthetic version of an active region of thymosin beta4, in equine urine and plasma by liquid chromatography-mass spectrometry. J Chromatogr A. 2012;1265:57-69. PMID: 23084823. DOI: 10.1016/j.chroma.2012.09.043
22. Billich A. Thymosin alpha1. SciClone Pharmaceuticals. Curr Opin Investig Drugs. 2002;3(5):698-707. PMID: 12090542. PubMed
23. Dominari A, Hathaway D 3rd, Pandav K, Matos W, Biswas S, Reddy G, et al. Thymosin alpha 1: A comprehensive review of the literature. World J Virol. 2020;9(5):67-78. PMID: 33362999. DOI: 10.5501/wjv.v9.i5.67
24. US Food and Drug Administration. Pharmacy Compounding Advisory Committee Meeting: Thymosin Alpha-1 Related Bulk Drug Substances. FDA Briefing Document. 2024. FDA
25. Sosne G, Dunn SP, Kim C. Thymosin beta4 significantly improves signs and symptoms of severe dry eye in a phase 2 randomized trial. Cornea. 2015;34(5):491-496. PMID: 25826322. DOI: 10.1097/ICO.0000000000000379
26. Bonini S, Sheha H, Hamrah P, et al. 0.1% RGN-259 (Thymosin beta4) Ophthalmic Solution promotes healing and improves comfort in neurotrophic keratopathy patients in a randomized, placebo-controlled, double-masked Phase III clinical trial. Clin Ophthalmol. 2022;16:4295-4310. PMC9820614
27. World Anti-Doping Agency. The Prohibited List. Montreal: WADA. WADA Prohibited List